Nothing Special   »   [go: up one dir, main page]

BR9909620A - Inibidores de metaloproteases de hidroxamato de pirrolidina substituìdo - Google Patents

Inibidores de metaloproteases de hidroxamato de pirrolidina substituìdo

Info

Publication number
BR9909620A
BR9909620A BR9909620-0A BR9909620A BR9909620A BR 9909620 A BR9909620 A BR 9909620A BR 9909620 A BR9909620 A BR 9909620A BR 9909620 A BR9909620 A BR 9909620A
Authority
BR
Brazil
Prior art keywords
compounds
present
metalloproteases
pharmaceutical compositions
formula
Prior art date
Application number
BR9909620-0A
Other languages
English (en)
Inventor
Menyan Cheng
Michael George Natchus
Biswanath De
Neil Gregory Almstead
Yetunde Olabisi Taiwo
Stanislaw Pikul
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of BR9909620A publication Critical patent/BR9909620A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Patente de Invenção: <B>"INIBIDORES DE METALOPROTEASES DE HIDROXAMATO DE PIRROLIDINA SUBSTITUìDO"<D>. A presente invenção proporciona compostos que são potentes inibidores de metaloproteases e que são eficazes nas condições de tratamento caracterizado pelo excesso de atividade dessas enzimas. Em particular, a presente invenção refere-se a compostos que apresentam uma estrutura de acordo com a Fórmula (I): onde R~ 1~, R~ 2~, X, Z, m e n são definidos abaixo. Esta invenção também inclui isómeros ópticos, diastereómeros e enantiómeros de Fórmula (I), e sais, amidas bioidrolisáveis, ésteres e imidas dos mesmos farmaceuticamente aceitáveis. Os compostos da presente invenção são úteis para o tratamento de doenças e condições que são caracterizadas pela atividade indesejável de metaloprotease. Conseq³entemente, a invenção proporciona adicionalmente composições farmacêuticas que compreendem esses compostos. A invenção ainda proporciona métodos de tratamento adicionais para enfermidades relacionadas com metaloproteases, usando esses compostos ou as composições farmacêuticas que os contêm.
BR9909620-0A 1998-04-14 1999-04-09 Inibidores de metaloproteases de hidroxamato de pirrolidina substituìdo BR9909620A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8166798P 1998-04-14 1998-04-14
PCT/US1999/007826 WO1999052868A1 (en) 1998-04-14 1999-04-09 Substituted pyrrolidine hydroxamate metalloprotease inhibitors

Publications (1)

Publication Number Publication Date
BR9909620A true BR9909620A (pt) 2000-12-19

Family

ID=22165611

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909620-0A BR9909620A (pt) 1998-04-14 1999-04-09 Inibidores de metaloproteases de hidroxamato de pirrolidina substituìdo

Country Status (21)

Country Link
US (1) US6329418B1 (pt)
EP (1) EP1073635A1 (pt)
JP (1) JP2002511448A (pt)
KR (1) KR100400507B1 (pt)
CN (1) CN1297436A (pt)
AR (1) AR029145A1 (pt)
AU (1) AU753048B2 (pt)
BR (1) BR9909620A (pt)
CA (1) CA2328211A1 (pt)
CO (1) CO5011039A1 (pt)
HU (1) HUP0102195A3 (pt)
ID (1) ID26925A (pt)
IL (1) IL138738A0 (pt)
NO (1) NO20005196L (pt)
NZ (1) NZ507076A (pt)
PE (1) PE20000425A1 (pt)
PL (1) PL343529A1 (pt)
SK (1) SK15462000A3 (pt)
TR (1) TR200002971T2 (pt)
WO (1) WO1999052868A1 (pt)
ZA (1) ZA200005047B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403632B1 (en) * 2000-03-01 2002-06-11 Bristol Myers Squibb Pharma Co Lactam metalloprotease inhibitors
US7018988B2 (en) 2000-03-27 2006-03-28 Applied Research Systems Ars Holding N.V. Pharmaceutically active pyrrolidine derivatives as Bax inhibitors
DE60120940T2 (de) 2000-03-27 2007-01-25 Applied Research Systems Ars Holding N.V. Pyrrolidin-derivate verwendbar als bax-inhibitoren
US8283135B2 (en) 2000-06-30 2012-10-09 The Procter & Gamble Company Oral care compositions containing combinations of anti-bacterial and host-response modulating agents
JP3983662B2 (ja) * 2000-07-19 2007-09-26 エフ．ホフマン−ラ ロシュ アーゲー ピリミジン誘導体
FR2819252A1 (fr) * 2001-01-11 2002-07-12 Servier Lab Nouveaux derives d'acide hydroxamique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
JP4350948B2 (ja) 2001-03-20 2009-10-28 ラボラトワール セローノ ソシエテ アノニム オキシトシン調節活性を有するピロリジンエステル誘導体
SE0103710D0 (sv) * 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
UA78058C2 (en) 2002-07-05 2007-02-15 Applied Research Systems Pyrrolidine derivative as oxitocin antagonists
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
CN1294120C (zh) * 2003-10-21 2007-01-10 山东大学 吡咯烷类基质金属蛋白酶抑制剂及其应用
CA2554767A1 (en) * 2004-02-26 2005-09-09 Applied Research Systems Ars Holding N.V. Method for preparing pyrrolidine oximes
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0401762D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
WO2006038265A1 (ja) * 2004-09-30 2006-04-13 Yutaka Imauchi 耳硬化症治療のための医薬組成物
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
CA2766696A1 (en) 2009-06-24 2010-12-29 Boehringer Ingelheim International Gmbh New compounds, pharmaceutical composition and methods relating thereto
US8481731B2 (en) 2009-06-24 2013-07-09 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
EP2845850A1 (en) 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
EP2886107A1 (en) 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
WO2016000920A1 (en) 2014-07-02 2016-01-07 ObsEva SA Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime useful in methods of treating conditions related to the ot-r activity

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3380992A (en) * 1965-06-14 1968-04-30 Upjohn Co Lincomycin derivatives and process for preparing same
US4377701A (en) * 1981-09-21 1983-03-22 E. R. Squibb & Sons, Inc. 4-Methylene-1-[[(alranoyl or arylcarbonyl)mercapto]acyl]proline and pipecolic acid
US4743587A (en) 1985-09-10 1988-05-10 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
US4771038A (en) 1986-01-21 1988-09-13 Ici Americas Inc. Hydroxamic acids
DK77487A (da) 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
ZW23187A1 (en) 1986-12-15 1988-06-29 Hoffmann La Roche Phosphinic acid derivatives
US5183900A (en) 1990-11-21 1993-02-02 Galardy Richard E Matrix metalloprotease inhibitors
US5892112A (en) 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
GB9102635D0 (en) 1991-02-07 1991-03-27 British Bio Technology Compounds
GB9107368D0 (en) 1991-04-08 1991-05-22 Smithkline Beecham Plc Novel compounds
WO1992022523A2 (en) 1991-06-14 1992-12-23 Research Corporation Technologies, Inc. Peptide derivatives of collagenase inhibitor
JPH05125029A (ja) 1991-11-06 1993-05-21 Yamanouchi Pharmaceut Co Ltd 新規なアミド化合物又はその塩
WO1993014112A1 (en) 1992-01-15 1993-07-22 Merck & Co., Inc. Substituted phosphinic acid-containing peptidyl derivatives as antidegenerative agents
AU4267293A (en) 1992-05-01 1993-11-29 British Biotech Pharmaceuticals Limited Use of MMP inhibitors
US5318964A (en) 1992-06-11 1994-06-07 Hoffmann-La Roche Inc. Hydroxamic derivatives and pharmaceutical compositions
AU666727B2 (en) 1992-06-25 1996-02-22 F. Hoffmann-La Roche Ag Hydroxamic acid derivatives
GB9215665D0 (en) 1992-07-23 1992-09-09 British Bio Technology Compounds
GB9223904D0 (en) 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
US5506242A (en) 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
GB9308695D0 (en) 1993-04-27 1993-06-09 Celltech Ltd Peptidyl derivatives
WO1994025434A1 (en) 1993-04-27 1994-11-10 Celltech Limited Peptidyl derivatives as metalloproteinase inhibitors
WO1995004033A1 (en) 1993-08-02 1995-02-09 Celltech Limited Succinamide derivatives, processes for their preparation and their use as gelatinase and collagenase inhibitors
GB9316162D0 (en) * 1993-08-04 1993-09-22 Zeneca Ltd Fungicides
US5545735A (en) 1993-10-04 1996-08-13 Merck & Co., Inc. Benzo-Fused Lactams promote release of growth hormone
US5470834A (en) 1993-10-06 1995-11-28 Florida State University Sulfoximine and suldodiimine matrix metalloproteinase inhibitors
US5403952A (en) 1993-10-08 1995-04-04 Merck & Co., Inc. Substituted cyclic derivatives as novel antidegenerative agents
UA48121C2 (uk) 1993-11-04 2002-08-15 Сінтекс (С.Ш.А.) Інк. Інгібітори матричних металопротеаз і фармацетична композиція на їх основі
GB9323165D0 (en) 1993-11-10 1994-01-05 Chiros Ltd Compounds
DE19581347T1 (de) 1994-01-20 1996-12-05 British Biotech Pharm Metalloproteinase-Inhibitoren
GB9401129D0 (en) 1994-01-21 1994-03-16 British Bio Technology Hydroxamic acid derivatives as metalloproteinase inhibitors
EP0740655B1 (en) 1994-01-22 1999-10-20 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US5514716A (en) 1994-02-25 1996-05-07 Sterling Winthrop, Inc. Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
GB9404046D0 (en) 1994-03-03 1994-04-20 Smithkline Beecham Corp Novel compounds
GB9405076D0 (en) 1994-03-16 1994-04-27 Inst Of Ophtalmology A medical use of matrix metalloproteinase inhibitors
DE4411311A1 (de) 1994-03-31 1995-10-05 Basf Ag Verfahren zur Herstellung von lagerstabilen wäßrigen Lösungen von Vinylamin-Einheiten enthaltenden Polymerisaten
GB9501737D0 (en) 1994-04-25 1995-03-22 Hoffmann La Roche Hydroxamic acid derivatives
AU2394795A (en) 1994-04-28 1995-11-29 Du Pont Merck Pharmaceutical Company, The Hydroxamic acid and amino acid derivatives and their use as anti-arthritic agents
JPH07304770A (ja) 1994-05-11 1995-11-21 Kanebo Ltd 新規ベンゾアゼピノン誘導体
DE69510198T2 (de) 1994-05-28 1999-10-28 British Biotech Pharmaceuticals Ltd., Cowley Succinyl hydroxamsäure-, n-formyl-n-hydroxy-aminocarbonsäure- und succinsäureamid-derivate und ihre verwendung als metalloprotease-inhibitoren
GB9411088D0 (en) 1994-06-03 1994-07-27 Hoffmann La Roche Hydroxylamine derivatives
GB9411598D0 (en) 1994-06-09 1994-08-03 Hoffmann La Roche Hydroxamic acid derivatives
GB9412350D0 (en) 1994-06-20 1994-08-10 Fujisawa Pharmaceutical Co New compound and its preparation
US5962529A (en) 1994-06-22 1999-10-05 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
GB9416897D0 (en) 1994-08-20 1994-10-12 British Biotech Pharm Metalloproteinase inhibitors
NZ325559A (en) 1995-12-08 2000-01-28 Agouron Pharmaceuticals Inc Ag Metalloproteinase inhibitors, pharmaceutical compoMetalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical usitions containing them and their pharmaceutical uses, and methods and intermediates useful for theises, and methods and intermediates useful for their preparation r preparation
DE69716449T2 (de) 1996-08-28 2003-08-07 The Procter & Gamble Company, Cincinnati Substituierte zyklische amine als metalloproteaseinhibitoren

Also Published As

Publication number Publication date
HUP0102195A3 (en) 2001-12-28
WO1999052868A1 (en) 1999-10-21
CO5011039A1 (es) 2001-02-28
CA2328211A1 (en) 1999-10-21
TR200002971T2 (tr) 2001-02-21
ZA200005047B (en) 2001-06-06
NZ507076A (en) 2003-04-29
AR029145A1 (es) 2003-06-18
AU3552299A (en) 1999-11-01
AU753048B2 (en) 2002-10-03
SK15462000A3 (sk) 2001-06-11
CN1297436A (zh) 2001-05-30
US6329418B1 (en) 2001-12-11
KR100400507B1 (ko) 2003-10-08
PE20000425A1 (es) 2000-07-13
HUP0102195A2 (hu) 2001-11-28
NO20005196L (no) 2000-12-14
PL343529A1 (en) 2001-08-27
NO20005196D0 (no) 2000-10-16
ID26925A (id) 2001-02-22
JP2002511448A (ja) 2002-04-16
IL138738A0 (en) 2001-10-31
KR20010042694A (ko) 2001-05-25
EP1073635A1 (en) 2001-02-07

Similar Documents

Publication Publication Date Title
BR9909620A (pt) Inibidores de metaloproteases de hidroxamato de pirrolidina substituìdo
BR9713465A (pt) Inibidores metalotprotease de amina cìclica sibstituìda
NO20024521L (no) Heterocyklisk sidekjede-inneholdende metalloproteaseinhibitorer
BR9713186A (pt) Inibidores de metaloprotease 1,3-diheterocìclicos
BR9810841A (pt) Inibidores de metaloprotease alicìclicos
BR9713182A (pt) Amidas de ácido fosfìnico como inibidores de metalo protease de matriz
BR0009244A (pt) Inibidores de metaloprotease di-hétero substituìdos
BR9712086A (pt) Inibidores1,4-heterocìclicos de metaloproteinases
BR9908275A (pt) Inibidores de enzimas fosfolipase
NO963499L (no) Hydroksaminsyre- og karboksylsyrederivater, fremgangsmåte for deres fremstilling og anvendelse derav
BR9712085A (pt) Inibidores de metaloprotease heterocìclicos
PT1058683E (pt) Inibidores da farnesil-transferase com uma estrutura de piperidina e seu processo de preparacao
FI942423A0 (fi) Sakkariinijohdannisia proteolyyttisen entsyymin inhibiittoreina
BR9917038A (pt) Composto, composição farmacêutica, método de modulação da atividade receptora de quimocinas, método de tratamento ou prevenção de doenças inflamatórias, método de tratamento ou prevenção de asma e método de tratamento ou prevenção de disfunções inflamatórias
BR9713178A (pt) Inbidores espirocìclicos da metaloprotease.
BR0008716A (pt) Inibidores de metaloprotease contendo alquenil ou alquinil
BR9712792A (pt) Inibidores de metaloprotease bidentada.
BR0315820A (pt) Inibidores de integrase de hiv, composições farmacêuticas e métodos para a sua utilização
BR0109328A (pt) Inibidores de metaloprotease n-substituìdos, contendo cadeia lateral heterocìclica
EA199900057A1 (ru) Ингибиторы матриксных металлопротеиназ
BR0008778A (pt) Análogos de prostaglandinas seletivos para fpc16 insaturados
BR0109348A (pt) Inibidores de metaloproteases n-substituìdos os quais contêm cadeias laterais carbocìclicas
BR0008776A (pt) Análogos de prostaglandinas fp-seletivosinsaturados c16
BR0014759A (pt) Inibidores de metaloprotease beta dissubstituìdos
BR9909870A (pt) Pirrolidinas como inibidores de neuraminidases

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6O, 7O E 8O ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007.